Nuformix plc (LON:NFX – Get Free Report) fell 18.5% during trading on Monday . The stock traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). 45,228,297 shares traded hands during mid-day trading, an increase of 84% from the average session volume of 24,550,277 shares. The stock had previously closed at GBX 0.07 ($0.00).
Nuformix Trading Down 16.7 %
The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35. The firm’s 50 day moving average is GBX 0.05 and its 200 day moving average is GBX 0.10. The company has a market capitalization of £409,655.00, a PE ratio of -1.63 and a beta of 1.22.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Nuformix
- What is the S&P/TSX Index?
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Profitably Trade Stocks at 52-Week Highs
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
